SCHEMBL3017211

SCHEMBL3017211

O=[N+]([O-])c1ccc(S(=O)(=O)C2CCN(c3nc(Cc4ccc(Cl)cc4Cl)cs3)CC2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
EPHX2 P34913 1/20 0.42
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
POLB P06746 2/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
DRD2 P14416 1/20 0.37
HTR2A P28223 1/20 0.37
HTR2C P28335 1/20 0.37
KCNH2 Q12809 1/20 0.37
GAA P10253 1/20 0.35
HTT P42858 1/20 0.35
DNM1L O00429 1/20 0.34
AR P10275 1/20 0.34
FLT1 P17948 1/20 0.34
FLT4 P35916 1/20 0.34
KDR P35968 1/20 0.34
KDM4E B2RXH2 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3003808 0.92 EPHX2 (0.46) MAPTSMN1; SMN2EPHX2POLBNPC1
SCHEMBL3013963 0.91 KDM1A (0.39) MAPTSMN1; SMN2EPHX2MEN1KMT2A
SCHEMBL3016617 0.90 EPHX2 (0.39) MAPTSMN1; SMN2EPHX2DRD2HTR2A
SCHEMBL3014243 0.88 EPHX2 (0.44) MAPTSMN1; SMN2EPHX2KMT2APOLB
SCHEMBL3012503 0.88 MAPT (0.43) MAPTSMN1; SMN2MEN1KMT2APOLB
SCHEMBL3020215 0.88 MAPT (0.48) MAPTSMN1; SMN2MEN1KMT2APOLB
SCHEMBL3008061 0.88 EPHX2 (0.55) MAPTSMN1; SMN2EPHX2MEN1KMT2A
SCHEMBL3007766 0.88 EPHX2 (0.44) MAPTSMN1; SMN2EPHX2MEN1KMT2A
SCHEMBL3018929 0.88 EPHX2 (0.42) MAPTSMN1; SMN2EPHX2RAB9ADRD2
SCHEMBL3001134 0.87 EPHX2 (0.42) MAPTSMN1; SMN2EPHX2RAB9ADRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA MAPT 18/4885SMN1; SMN2 1/4885EPHX2 4409/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.